Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 6/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 4/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401284 | 0.84 | HSD17B10 (0.47) | F2CAPN1GHSRF10PLG | |
| SCHEMBL1401268 | 0.84 | OPRD1 (0.48) | F2CAPN1GHSRTACR1MMP9 | |
| SCHEMBL3266844 | 0.83 | GHSR (0.48) | F2CAPN1GHSRMMP9MMP8 | |
| SCHEMBL6320694 | 0.83 | MMP9 (0.56) | F2GHSRMMP9MMP8 | |
| SCHEMBL8235025 | 0.82 | GHSR (0.49) | F2GHSRMMP9MMP8 | |
| SCHEMBL1401593 | 0.81 | F2 (0.50) | F2CAPN1GHSRTACR1MMP9 | |
| SCHEMBL3268068 | 0.81 | GHSR (0.44) | F2CAPN1GHSRTACR1MMP9 | |
| SCHEMBL6316765 | 0.81 | BDKRB2 (0.45) | F2CAPN1GHSRTACR1MMP9 | |
| SCHEMBL1401188 | 0.80 | OPRD1 (0.44) | F2CAPN1GHSRTACR1F10 | |
| SCHEMBL4427112 | 0.80 | FCER2 (0.53) | F2GHSRTACR1MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789067-B8 | Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system | HELSINN HEALTHCARE SA (CH) | 2012-08-15 | — | — | EP | disclosed |
| EP-2146732-A1 | METHODS OF TREATING OR PREVENTING EMESIS USING GROWTH HORMONE SECRETAGOGUES | Helsinn Therapeutics (U.S.), Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008124183-A1 | METHODS OF TREATING OR PREVENTING EMESIS USING GROWTH HORMONE SECRETAGOGUES | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-1789067-A2 | METHOD OF STIMULATING THE MOTILITY OF THE GASTROINTESTINAL SYSTEM USING GROWTH HORMONE SECRETAGOGUES | Sapphire Therapeutics, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006020930-A2 | METHOD OF STIMULATING THE MOTILITY OF THE GASTROINTESTINAL SYSTEM USING GROWTH HORMONE SECRETAGOGUES | SAPPHIRE THERAPEUTICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |